Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 70 - 74 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.90359 İndeks Tarihi: 18-07-2022
Apremilast
Öz: Apremilast is an orally used small-molecule inhibitor of phosphodiesterase-4. It has been approved for the treatment of adult patients with
psoriatic arthritis and moderate to severe plaque psoriasis. Clinical studies have reported that it is also effective in hairy skin and nail psoriasis,
generalized pustular psoriasis, and palmoplantar pustulosis. In psoriasis vulgaris, a PASI75 response was achieved in 30-70% of the patients
in 12-16 weeks. It is generally well-tolerated, and its most common side effects are diarrhea, headache, and nausea, all of which disappear in
time.
Anahtar Kelime: Apremilast
Öz: Apremilast, oral olarak kullanılan, küçük moleküllü fosfodiesteraz-4 inhibitörüdür. Psoriatik artritli ve orta/şiddetli plak psoriasisli yetişkin
hastaların tedavisinde onaylıdır. Yapılan klinik çalışmalarda saçlı deri, tırnak psoriasisi, jeneralize püstüler psoriasis ve palmoplantar püstülosiste
de etkili olduğu bildirilmiştir. Psoriasis vulgariste PAŞİ75 cevabı hastaların %30-70’inde 12-16 haftada alınmıştır. Genel olarak iyi tolere edilir,
diyare, baş ağrısı ve bulantı en sık görülen yan etkiler olup zamanla geriler.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Kelly JB 3rd, Foley P, Strober BE: Current and future oral systemic therapies for psoriasis. Dermatol Clin 2015;33:91-109.
- 2. Del Rosso JQ, Kircik L: Oral apremilast for the treatment of plaque psoriasis. J Clin Aesthetic Dermatol 2016;9:43-8.
- 3. Gooderham M, Papp K: Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast. Bio Drugs Clin Immunother Biopharm Gene Ther 2015;29:327-39.
- 4. Keating GM: Apremilast: A review in psoriasis and psoriatic arthritis. Adis Drug Evaluation Drugs 2017;77:459-72
- 5. Schafer PH, Parton A, Capone L, et al.: Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014;26:2016-29.
- 6. Perez-Aso M, Montesinos MC, Mediero A, et al.: Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther 2015;17:249.
- 7. Papp K, Reich K, Leonardi CL, et al.: Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015;73:37-49.
- 8. Paul C, Cather J, Gooderham M, et al.: Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015;173:1387-99.
- 9. Bissonnette R, Pariser DM, Wasel NR, et al.: Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016;75:99-105.
- 10. Crowley J, Thaçi D, Joly P, et al.: Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017;77:310-7.
- 11. Rich P, Gooderham M, Bachelez H, et al.: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol 2016;74:134-42.
- 12. Cutolo M, Myerson GE, Fleischmann RM, et al.: A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol 2016;43:1724-34.
- 13. Edwards CJ, Blanco FJ, Crowley J, et al.: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016;75:1065-73.
- 14. Reich K, Gooderham M, Green L, et al.: The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebocontrolled trial (LIBERATE). J Eur Acad Dermatol Venereol 2017;31:507-17.
- 15. Vujic I, Herman R, Sanlorenzo M, et al.: Apremilast in psoriasis - a prospective real-world study JEADV 2018;32:254-9.
- 16. Afra TP, Fazmi M, Dogra S: Apremilast in psoriasis and beyond: big hopes on a small molecule. Ind Dermatol Online J 2019;10:1-12.
- 17. Haebich G, Kalavala M: Successful treatment of refractory palmoplantar pustulosis with apremilast. Clin Exp Dermatol 2017;42:471-3.
- 18. AbuHilal M, Walsh S, Shear N: Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg 2016;20:313-6.
- 19. Vakharia PP, Orrel KA, Lee D, et al.: Apremilast and suicidality: a retropspective analysis of three large databases: the FAERS, Eudra Vigilance an a large singlecentre US patient population. J Eur Acad Dermatol Venereol 2017;13:e463-4.
- 20. Nast A, Amelunxen L, Augustin M, et al.: S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges 2018;16:645-69.
- 21. Kaushik SB, Lebwohl MG: Psoriasis: Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol 2019;58:649-58.
- 22. Kaushik SB, Lebwohl MG: Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol 2019;80;43-53.
- 23. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019;80;27-40.
- 24. Reddy SP, Shah VV, Wu JJ: Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol 2017;31:e481-2.
- 25. Gualtierotti R, Parisi M, Ingegloni F: Perioperative management of patients with inflammatory rheumatic diseases undergoing major orthopaedic surgery: a practical overview. Adv Ther 2018;35:439-56.
- 26. Ricardo JW, Lipner SR: Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the Covid-19. Dermatol Ther 2020;33:e13687.
- 27. Wang C, Marius M, Baker C, Foley P: COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement. Australas J Dermatol 2020;61:210-6.
| APA | KUNDAKCI N (2022). Apremilast. , 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| Chicago | KUNDAKCI NİHAL Apremilast. (2022): 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| MLA | KUNDAKCI NİHAL Apremilast. , 2022, ss.70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| AMA | KUNDAKCI N Apremilast. . 2022; 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| Vancouver | KUNDAKCI N Apremilast. . 2022; 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| IEEE | KUNDAKCI N "Apremilast." , ss.70 - 74, 2022. 10.4274/turkderm.galenos.2022.90359 |
| ISNAD | KUNDAKCI, NİHAL. "Apremilast". (2022), 70-74. https://doi.org/10.4274/turkderm.galenos.2022.90359 |
| APA | KUNDAKCI N (2022). Apremilast. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| Chicago | KUNDAKCI NİHAL Apremilast. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| MLA | KUNDAKCI NİHAL Apremilast. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| AMA | KUNDAKCI N Apremilast. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| Vancouver | KUNDAKCI N Apremilast. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 70 - 74. 10.4274/turkderm.galenos.2022.90359 |
| IEEE | KUNDAKCI N "Apremilast." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.70 - 74, 2022. 10.4274/turkderm.galenos.2022.90359 |
| ISNAD | KUNDAKCI, NİHAL. "Apremilast". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 70-74. https://doi.org/10.4274/turkderm.galenos.2022.90359 |
